A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models.
Emanuel S, Gruninger RH, Fuentes-Pesquera A, Connolly PJ, Seamon JA, Hazel S, Tominovich R, Hollister B, Napier C, D'Andrea MR, Reuman M, Bignan G, Tuman R, Johnson D, Moffatt D, Batchelor M, Foley A, O'Connell J, Allen R, Perry M, Jolliffe L, Middleton SA.
Emanuel S, et al.
Mol Pharmacol. 2004 Sep;66(3):635-47. doi: 10.1124/mol.104.000638.
Mol Pharmacol. 2004.
PMID: 15322256